Texas named a best state for remote work

work from home, y'all

A new list Texas at No. 6 among the best states for people seeking remote jobs. Photo vie Getty Images

Economic development boosters regularly tout Texas as a business-friendly state. Now, they can add another positive attribute: Texas ranks as one of the top remote-work-friendly states in the U.S.

A new list from the CareerCloud career platform puts Texas at No. 6 among the best states for people seeking remote jobs. Utah leads the ranking, followed by Colorado, the District of Columbia, Washington, and Virginia.

Helping lift Texas toward the top of the ranking is its No. 3 spot among the states projected to see the most growth (26 percent) in remote-friendly jobs from 2018 to 2028. Utah ranks first (41.7 percent) and Colorado ranks second (30.8 percent).

CareerCloud judged states on two other factors: broadband internet access, with Texas holding the No. 23 spot, and employment per 1,000 remote-friendly jobs, with Texas at No. 24.

These are the 14 jobs that CareerCloud deemed remote-friendly:

  • Accountant
  • Actuary
  • Computer network architect
  • Computer systems manager
  • Computer systems analyst
  • Database administrator
  • Information security analyst
  • Management analyst
  • Market research analyst
  • Marketing manager
  • Mathematician
  • Software developer
  • Statistician
  • Web developer

A list published last year by TheStreet, an investment website, backs up Texas' position in the CareerCloud ranking. The Street names nine places in Texas among the 30 best U.S. cities for remote work during the pandemic: El Paso, Plano, Garland, Corpus Christi, San Antonio, Austin, Fort Worth, Arlington, and Dallas. Houston didn't make the cut.

By contrast, not a single city in Texas appears on a list published by Money Crashers, a personal finance website, of the 20 best places in the U.S. to live and work remotely in 2021. Likewise, Livability.com leaves Texas cities off its list of the country's top 10 remote-ready cities for 2021.

A March 21 post authored by Tory Gattis, editor of the Houston Strategies blog and founding senior fellow at the Center for Opportunity Urbanism, makes the case for and against Houston as a remote-work hub.

Gattis lays out these factors in favor of Houston as a remote-friendly place:

  • Most affordable global city in the U.S., offering big-city amenities at a reasonable cost
  • Lots of Houston ex-pats who might come home to be closer to family and friends
  • Strong community culture for such a large, diverse city
  • Healthy immigrant ecosystem

According to Gattis, these are some of the unfavorable factors for Houston as a remote-friendly spot:

  • Not a classic "lifestyle" destination like Austin, Denver, or Miami
  • Big-city problems like traffic and crime
  • Climate susceptible to hurricanes, flooding, heat, and humidity

"Overall," Gattis writes, "I'd say we're likely to come out fairly well — not as good as the popular lifestyle cities, but much better than the unaffordable superstar cities like SF and NYC."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”